17595233|t|Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease.
17595233|a|BACKGROUND AND AIMS: A number of antibodies against microbial epitopes or self-antigens have been associated with Crohn's disease. The development of antibodies reflects a loss of tolerance to intestinal bacteria that underlies Crohn's disease, resulting in an exaggerated adaptive immune response to these bacteria. It was hypothesised that the development of antimicrobial antibodies is influenced by the presence of genetic variants in pattern recognition receptor genes. The aim of this study was therefore to investigate the influence of mutations in these innate immune receptor genes (nucleotide oligomerisation domain (NOD) 2/caspase recruitment domain (CARD) 15, NOD1/CARD4, TUCAN/CARDINAL/CARD8, Toll-like receptor (TLR) 4, TLR2, TLR1 and TLR6) on the development of antimicrobial and antiglycan antibodies in inflammatory bowel disease (IBD). Materials and METHODS: A cohort of 1163 unrelated patients with IBD (874 Crohn's disease, 259 ulcerative colitis, 30 indeterminate colitis) and 312 controls were analysed for anti-Saccharomyces cerevisiae antibodies (gASCA) IgG, anti-laminaribioside antibodies (ALCA) IgG, anti-chitobioside antibodies (ACCA) IgA, anti-mannobioside antibodies (AMCA) IgG and outer membrane porin (Omp) IgA and were genotyped for variants in NOD2/CARD15, TUCAN/CARDINAL/CARD8, NOD1/CARD4, TLR4, TLR1, TLR2 and TLR6. RESULTS: When compared with Crohn's disease patients without CARD15 mutations, the presence of at least one CARD15 variant in Crohn's disease patients more frequently led to gASCA positivity (66.1% versus 51.5%, p < 0.0001) and ALCA positivity (43.3% versus 34.9%, p = 0.018) and higher gASCA titers (85.7 versus 51.8 ELISA units, p < 0.0001), independent of ileal involvement. A gene dosage effect, with increasing gASCA and ALCA positivity for patients carrying none, one and two CARD15 variants, respectively, was seen for both markers. Similarly, Crohn's disease patients carrying NOD1/CARD4 indel had a higher prevalence of gASCA antibodies than wild-type patients (63.8% versus 55.2%, p = 0.014), also with a gene dosage effect. An opposite effect was observed for the TLR4 D299G and TLR2 P631H variants, with a lower prevalence of ACCA antibodies (23.4% versus 35%, p = 0.013) and Omp antibodies (20.5% versus 34.6%, p = 0.009), respectively. CONCLUSION: Variants in innate immune receptor genes were found to influence antibody formation against microbial epitopes. In this respect, it is intriguing that an opposite effect of CARD15 and TLR4 variants was observed. These findings may contribute to an understanding of the aetiology of the seroreactivity observed in IBD.
17595233	97	105	patients	OrganismTaxon	9606
17595233	111	137	inflammatory bowel disease	DiseaseOrPhenotypicFeature	D015212
17595233	253	268	Crohn's disease	DiseaseOrPhenotypicFeature	D003424
17595233	343	351	bacteria	OrganismTaxon	2
17595233	367	382	Crohn's disease	DiseaseOrPhenotypicFeature	D003424
17595233	446	454	bacteria	OrganismTaxon	2
17595233	701	723	innate immune receptor	GeneOrGeneProduct	10333,10392,22900,64127,7096,7097,7099
17595233	731	772	nucleotide oligomerisation domain (NOD) 2	GeneOrGeneProduct	64127
17595233	773	809	caspase recruitment domain (CARD) 15	GeneOrGeneProduct	64127
17595233	811	815	NOD1	GeneOrGeneProduct	10392
17595233	816	821	CARD4	GeneOrGeneProduct	10392
17595233	823	828	TUCAN	GeneOrGeneProduct	22900
17595233	829	837	CARDINAL	GeneOrGeneProduct	22900
17595233	838	843	CARD8	GeneOrGeneProduct	22900
17595233	845	871	Toll-like receptor (TLR) 4	GeneOrGeneProduct	7099
17595233	873	877	TLR2	GeneOrGeneProduct	7097
17595233	879	883	TLR1	GeneOrGeneProduct	7096
17595233	888	892	TLR6	GeneOrGeneProduct	10333
17595233	959	985	inflammatory bowel disease	DiseaseOrPhenotypicFeature	D015212
17595233	987	990	IBD	DiseaseOrPhenotypicFeature	D015212
17595233	1043	1051	patients	OrganismTaxon	9606
17595233	1057	1060	IBD	DiseaseOrPhenotypicFeature	D015212
17595233	1066	1081	Crohn's disease	DiseaseOrPhenotypicFeature	D003424
17595233	1087	1105	ulcerative colitis	DiseaseOrPhenotypicFeature	D003093
17595233	1124	1131	colitis	DiseaseOrPhenotypicFeature	D003092
17595233	1173	1197	Saccharomyces cerevisiae	OrganismTaxon	4932
17595233	1417	1421	NOD2	GeneOrGeneProduct	64127
17595233	1422	1428	CARD15	GeneOrGeneProduct	64127
17595233	1430	1435	TUCAN	GeneOrGeneProduct	22900
17595233	1436	1444	CARDINAL	GeneOrGeneProduct	22900
17595233	1445	1450	CARD8	GeneOrGeneProduct	22900
17595233	1452	1456	NOD1	GeneOrGeneProduct	10392
17595233	1457	1462	CARD4	GeneOrGeneProduct	10392
17595233	1464	1468	TLR4	GeneOrGeneProduct	7099
17595233	1470	1474	TLR1	GeneOrGeneProduct	7096
17595233	1476	1480	TLR2	GeneOrGeneProduct	7097
17595233	1485	1489	TLR6	GeneOrGeneProduct	10333
17595233	1519	1534	Crohn's disease	DiseaseOrPhenotypicFeature	D003424
17595233	1535	1543	patients	OrganismTaxon	9606
17595233	1552	1558	CARD15	GeneOrGeneProduct	64127
17595233	1599	1605	CARD15	GeneOrGeneProduct	64127
17595233	1617	1632	Crohn's disease	DiseaseOrPhenotypicFeature	D003424
17595233	1633	1641	patients	OrganismTaxon	9606
17595233	1937	1945	patients	OrganismTaxon	9606
17595233	1973	1979	CARD15	GeneOrGeneProduct	64127
17595233	2042	2057	Crohn's disease	DiseaseOrPhenotypicFeature	D003424
17595233	2058	2066	patients	OrganismTaxon	9606
17595233	2076	2080	NOD1	GeneOrGeneProduct	10392
17595233	2081	2086	CARD4	GeneOrGeneProduct	10392
17595233	2152	2160	patients	OrganismTaxon	9606
17595233	2266	2270	TLR4	GeneOrGeneProduct	7099
17595233	2271	2276	D299G	SequenceVariant	rs4986790
17595233	2281	2285	TLR2	GeneOrGeneProduct	7097
17595233	2286	2291	P631H	SequenceVariant	p|SUB|P|631|H
17595233	2465	2487	innate immune receptor	GeneOrGeneProduct	10333,10392,22900,64127,7096,7097,7099
17595233	2626	2632	CARD15	GeneOrGeneProduct	64127
17595233	2637	2641	TLR4	GeneOrGeneProduct	7099
17595233	2766	2769	IBD	DiseaseOrPhenotypicFeature	D015212
17595233	Association	7097	D015212	Novel
17595233	Association	7099	D015212	Novel
17595233	Negative_Correlation	p|SUB|P|631|H	D015212	Novel
17595233	Negative_Correlation	rs4986790	D015212	Novel
17595233	Association	64127	D015212	Novel
17595233	Association	D003424	64127	Novel
17595233	Association	D003424	10392	Novel